MedPath

Randomized study of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) with vs. without rapid on-site cytologic evaluation (ROSE) in the diagnosis of lung cancer

Phase 3
Conditions
ung cancer
Registration Number
JPRN-UMIN000001334
Lead Sponsor
agoya Medical Center
Brief Summary

Twelve patients with visible endobronchial lesions were excluded in the analysis. Thus, a total of 108 patients (55 in ROSE group; 53 in non-ROSE group) were analyzed. Additional procedures including EBUS-TBNA for lesions other than the main target lesion and/or transbronchial biopsy in the same setting were performed in 11% of patients in the ROSE group and 57% in the non-ROSE group (p < 0.001). Mean puncture number was significantly fewer in the ROSE group (2.2 vs. 3.1 punctures, p < 0.001). Mean bronchoscopy time was similar between both groups (22.3 vs. 22.1 min, p = 0.95). The sensitivity and accuracy for diagnosing lung cancer were 88% and 89% in the ROSE group, and 86% and 89% in the non-ROSE group, respectively. No complications were associated with the procedures.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
120
Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients with known lung cancer (e.g., mediastinal staging purposes) 2. Endobronchial lesions 3. Patients with severe concomitant medical illness 4. Bleeding tendency 5. Pregnant woman 6. Other clinical difficulties in this study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. Yields for eliminating the need for additional bronchoscopic procedures
Secondary Outcome Measures
NameTimeMethod
1. Diagnostic yields (EBUS-TBNA, overall bronchoscopy) 2. Accuracy of EBUS-TBNA 3. Number of needle passes 4. Time of procedure (EBUS-TBNA, overall bronchoscopy) 5. Accuracy of ROSE 6. Frequency of adverse effects
© Copyright 2025. All Rights Reserved by MedPath